


WHI-P180

09/19

ALTERNATE NAMES: 3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol; 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline; Janex3; 4-(3'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline

CATALOG #: B2908-5 5 mg
B2908-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₆H₁₅N₃O₃

MOLECULAR WEIGHT: 297.31

CAS NUMBER: 211555-08-7

APPEARANCE: A crystalline solid

PURITY: >98%

SOLUBILITY: ~15 mg/ml in DMSO
~25 mg/ml in DMF

DESCRIPTION: WHI-P180 is a multi-kinase inhibitor. It inhibits human proto-oncogene receptor tyrosine kinase RET (Rearranged during Transfection) and kinase insert domain receptor (KDR) with IC₅₀ values of 4.5 nM and 66 nM respectively. It inhibits epidermal growth factor receptor (EGFR) kinase with an IC₅₀ of 4.0 μM and also inhibits Janus kinase 3 (JAK3). It exhibits potent anti-graft-versus-host disease activity and IgE-mediated mast cell responses *in vitro* and *in vivo*.

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Ghosh, S., Jennissen, J.D., Liu, X.P., et al. 4-[3-Bromo-4-hydroxyphenyl]amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride. *Acta. Crystallogr. C.* 57(Pt 1), 76-78 (2001).
2. Cetkovic-Cvrlje, M., Roers, B.A., Schonhoff, D., et al. Treatment of post-bone marrow transplant acute graft-versus-host disease with a rationally designed JAK3 inhibitor. *Leuk. Lymphoma.* 43(7), 1447-1453 (2002).
3. Chen, C.-L., Malaviya, R., Navara, C., et al. Pharmacokinetics and biologic activity of the novel mast cell inhibitor, 4-(3-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice. *Pharm. Res.* 16(1), 117-122 (1999).
4. Newton, R., Bowler, K.A., Burns, E.M., et al. The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. *Eur. J. Med. Chem.* 13, 20-32 (2016).

RELATED PRODUCTS:

Foretinib (Cat. No. 9476)
 Dasatinib (BMS-354825, Sprycel) (Cat. No. 1586)
 EZSolution™ Dasatinib (Cat. No. 2029)
 EZSolution™ Cerdulatinib (Cat. No. B2482)
 Regorafenib (Cat. No. 2891)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**